secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2026-08-04T20:16:02+00:00
Accession:  0000012208-26-000046
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q2 revenue flat at $651M; announces restructuring plan with $80-90M charges
--------------------------------------------------------------------------------

- Q2 net sales $651.0M flat YoY; GAAP diluted EPS $13.85, non-GAAP diluted EPS $2.62.
- Clinical Diagnostics grew; Life Science soft but digital PCR revenue up >20%.
- Restructuring plan initiated July 31, 2026; pre-tax charges estimated $80-90M, primarily severance and facility closures.
- Plan expected substantially complete by end of FY2027; includes position eliminations and function consolidation.
- Generated $98.7M operating cash flow; repurchased ~$32M shares; full-year outlook reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220826000046/0000012208-26-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220826000046/bio-20260731.htm
  HTML page:      https://secwatch.observer/filing/0000012208-26-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer